O2881

Sigma-Aldrich

Oxybutynin chloride

≥98% (TLC), powder

Synonym(s):
α-Phenylcyclohexaneglycolic acid 4-(diethylamino)-2-butynyl ester hydrochloride
Empirical Formula (Hill Notation):
C22H31NO3 · HCl
CAS Number:
Molecular Weight:
393.95
EC Number:
MDL number:
PubChem Substance ID:
NACRES:
NA.77

Quality Level

assay

≥98% (TLC)

form

powder

color

white

solubility

H2O: 50 mg/mL

originator

Johnson & Johnson

SMILES string

Cl.CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)c2ccccc2

InChI

1S/C22H31NO3.ClH/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20;/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3;1H

InChI key

SWIJYDAEGSIQPZ-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Packaging

1, 5 g in glass bottle
500 mg in glass bottle

Biochem/physiol Actions

Muscarinic acetylcholine receptor antagonist; inhibits proliferation of bladder smooth muscle cells, perhaps by downregulation of growth promoting genes.

Features and Benefits

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
This compound is also offered as part of Sigma′s Library of Pharmacologically Active Compounds (LOPAC®1280), a biologically annotated collection of high-quality, ready-to-screen compounds. Click here to learn more.

Legal Information

LOPAC is a registered trademark of Sigma-Aldrich Co. LLC

pictograms

Exclamation mark

signalword

Warning

hcodes

hazcat

Acute Tox. 4 Oral

storage_class_code

13 - Non Combustible Solids

WGK Germany

WGK 3

Flash Point F

Not applicable

Flash Point C

Not applicable

Personal Protective Equipment

dust mask type N95 (US),Eyeshields,Gloves

Certificate of Analysis

Certificate of Origin

Naoki Aizawa et al.
European urology, 62(6), 1165-1173 (2012-09-18)
Mirabegron is the first β3-adrenoceptor agonist that is clinically effective for overactive bladder. The effects of mirabegron on primary bladder mechanosensitive single-unit afferent activities (SAAs) and bladder microcontractions were evaluated and compared with the effects of oxybutynin. Female Sprague-Dawley rats...
P Tauzin-Fin et al.
Annales francaises d'anesthesie et de reanimation, 31(7-8), 605-608 (2012-07-04)
Catheter-related bladder discomfort (CRBD) is an unrecognized clinical event. Symptoms of CRBD secondary to an indwelling urinary catheter mimic those of an overactive bladder, i.e. urinary frequency and urgency with or without urge incontinence. Stimulation of muscarinic receptors located in...
Daniele Zama et al.
Pediatric transplantation, 17(1), 86-91 (2012-12-13)
HC is a possible cause of morbidity and extended hospitalization after HSCT. Recent studies have reported the efficiency of HOT in adult patients who underwent allogeneic HSCT, but data in children are scarce. We report our single center experience with...
Theodore M Johnson et al.
BJU international, 112(1), 100-108 (2013-03-02)
WHAT'S KNOWN ON THE SUBJECT? AND WHAT DOES THE STUDY ADD?: Nocturia is a common and bothersome lower urinary tract symptom, particularly in men. Many single drug therapies have limited benefit. For men who have persistent nocturia despite alpha-blocker therapy...
R Cremer
Der Urologe. Ausg. A, 51(7), 991-995 (2012-06-15)
Paraplegic spina bifida patients often suffer from disturbed sweat secretion in the paretic regions. A diminished sweat production of caudal parts of the body is compensated by an increased secretion of sweat in parts cranial to the lesion to maintain...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service